These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 31275538)

  • 1. Management of perioperative hemostasis in a severe hemophilia A patient with inhibitors on emicizumab using global hemostasis assays.
    Kizilocak H; Yukhtman CL; Marquez-Casas E; Lee J; Donkin J; Young G
    Ther Adv Hematol; 2019; 10():2040620719860025. PubMed ID: 31275538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of bypassing agents in patients on emicizumab using global hemostasis assays.
    Kizilocak H; Marquez-Casas E; Phei Wee C; Malvar J; Carmona R; Young G
    Haemophilia; 2021 Jan; 27(1):164-172. PubMed ID: 33245833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful Perioperative Combination of High-Dose FVIII Therapy Followed by Emicizumab in a Patient with Hemophilia A with Inhibitors.
    Okamoto S; Suzuki N; Suzuki A; Suzuki S; Tamura S; Suzuki M; Takahashi N; Kojima T; Kanematsu T; Kojima T; Kiyoi H; Ishiguro N; Matsushita T
    TH Open; 2019 Oct; 3(4):e364-e366. PubMed ID: 31815248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility of using thrombin generation assay (TGA) for monitoring bypassing agent therapy in patients with hemophilia having inhibitors.
    Ay Y; Balkan C; Karapinar DY; Akin M; Bilenoglu B; Kavakli K
    Clin Appl Thromb Hemost; 2013; 19(4):389-94. PubMed ID: 22395575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hemostatic management of hemophilia].
    Tokugawa T
    Rinsho Ketsueki; 2022; 63(9):1212-1222. PubMed ID: 36198547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concomitant Use of rFVIIa and Emicizumab in People with Hemophilia A with Inhibitors: Current Perspectives and Emerging Clinical Evidence.
    Linari S; Castaman G
    Ther Clin Risk Manag; 2020; 16():461-469. PubMed ID: 32547043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy of bypassing agents in surgery of hemophilia patients with inhibitors.
    Ju HY; Jang HL; Park YS
    Blood Res; 2015 Sep; 50(3):173-8. PubMed ID: 26457285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of surgery in persons with hemophilia A receiving emicizumab prophylaxis: data from a national hemophilia treatment center.
    Cohen O; Levy-Mendelovich S; Budnik I; Ludan N; Lyskov SK; Livnat T; Avishai E; Efros O; Lubetsky A; Lalezari S; Misgav M; Brutman-Barazani T; Kenet G; Barg AA
    Res Pract Thromb Haemost; 2023 Aug; 7(6):102178. PubMed ID: 37876894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clot waveform analysis for perioperative hemostatic monitoring of arthroscopic synovectomy in a pediatric patient with hemophilia A and inhibitor receiving emicizumab prophylaxis.
    Mizumachi K; Tsumura Y; Nakajima Y; Koh K; Nogami K
    Int J Hematol; 2021 Jun; 113(6):930-935. PubMed ID: 33566316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emicizumab Augments Thrombus Formation in Whole Blood from Patients with Hemophilia A under High Shear Flow Conditions.
    Yaoi H; Shida Y; Kitazawa T; Shima M; Nogami K
    Thromb Haemost; 2021 Mar; 121(3):279-286. PubMed ID: 32906155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determining the approximate factor VIII level of patients with severe haemophilia A on emicizumab using in vivo global haemostasis assays.
    Kizilocak H; Marquez-Casas E; Malvar J; Carmona R; Young G
    Haemophilia; 2021 Sep; 27(5):730-735. PubMed ID: 34115433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events.
    Patel AM; Corman SL; Chaplin S; Raimundo K; Sidonio RF
    J Med Econ; 2019 Dec; 22(12):1328-1337. PubMed ID: 31530050
    [No Abstract]   [Full Text] [Related]  

  • 13. Safe and Successful Surgical Outcome in Persons with Hemophilia A with and without Inhibitors Treated with Emicizumab: A Large, Single Center, Real-World Experience.
    Castaman G; Linari S; Pieri L; Carulli C; Prosperi P; Tonelli P; Demartis F; Fjerza R; Attanasio M; Coppo M; Salvianti F
    J Clin Med; 2023 Mar; 12(6):. PubMed ID: 36983317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management and Outcomes of Invasive Procedures in Individuals with Hemophilia A on Emicizumab Prophylaxis: A Single Center Experience.
    Rener K; Anžej Doma S; Fink M; Podgornik H; Preložnik Zupan I
    Hematol Rep; 2023 Nov; 15(4):597-607. PubMed ID: 37987318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis.
    Batsuli G; Zimowski KL; Tickle K; Meeks SL; Sidonio RF
    Haemophilia; 2019 Sep; 25(5):789-796. PubMed ID: 31373431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Emicizumab: a paradigm shift in hemophilia treatment].
    Nogami K
    Rinsho Ketsueki; 2020; 61(5):536-541. PubMed ID: 32507821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surgical Experience from the STASEY Study of Emicizumab Prophylaxis in People with Hemophilia A with Factor VIII Inhibitors.
    Castaman G; Peyvandi F; Kremer Hovinga JA; Schutgens REG; Robson S; Moreno K; Jiménez-Yuste V
    TH Open; 2024 Jan; 8(1):e42-e54. PubMed ID: 38222041
    [No Abstract]   [Full Text] [Related]  

  • 18. A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa/X.
    Ogiwara K; Nogami K; Matsumoto N; Noguchi-Sasaki M; Hirata M; Soeda T; Shima M
    Int J Hematol; 2020 Nov; 112(5):621-630. PubMed ID: 32748217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agents.
    Hartmann R; Feenstra T; Valentino L; Dockal M; Scheiflinger F
    J Thromb Haemost; 2018 Jun; ():. PubMed ID: 29888855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The future of bypassing agents for hemophilia with inhibitors in the era of novel agents.
    Shapiro AD; Mitchell IS; Nasr S
    J Thromb Haemost; 2018 Dec; 16(12):2362-2374. PubMed ID: 30264916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.